Drug Delivery: Faculty and Staff

Kristy_Ainslie

Kristy Ainslie, PhD

The Ainslie Lab focuses on modulation of immune responses to prevent and treat cancer, infectious and autoimmune diseases.

Owen Fenton, PhD

The Fenton Lab develops RNA nanomedicines for the treatment of cancers and other diseases

shawn_hingtgen

Shawn Hingtgen, PhD

The Hingtgen Lab develops engineered stem cell-based therapies for brain cancers and other tumors.

Yevgeny Brudno, PhD

The Brudno Lab develops technologies to transform cell therapy manufacturing and delivery, including bedside CAR T cell treatments and novel gene therapies for cancer.

alexander_kabanov

Alexander “Sasha” Kabanov, PhD

The Kabanov Lab focuses on nanomedicines for delivery of small drugs, nucleic acids and polypeptides to treat cancers and diseases of the central nervous system.

sam_lai

Sam Lai, PhD

The Lai Lab focuses on infectious diseases at mucosal surfaces, targeted drug delivery and nanoparticle-immune interactions.

Juliane-Nguyen

Juliane Nguyen, PhD

The Nguyen Lab focuses on developing genetically encoded and genetically engineered biotherapeutics for the treatment of cancer, myocardial infarction, colitis, and other diseases.

schoenfisch_mark

Mark Schoenfisch, PhD

The Schoenfisch Lab focuses on designing macromolecules for nitric oxide release and detection, glucose monitoring devices for diabetes and superhydrophobic interfaces.

Learn more about Pharmacoengineering and Molecular Pharmaceutics

Soumya Rahima Benhabbour, PhD

UNC/NCSU Joint Department of Biomedical Engineering at UNC Chapel Hill

Dr. Benhabbour’s research focuses on the development of novel delivery platforms and polymer-based devices that can treat or prevent disease.

paul_dayton

Paul Dayton, PhD

UNC/NCSU Joint Department of Biomedical Engineering at UNC Chapel Hill

Dr. Dayton is the William R. Kenan Distinguished Professor of Biomedical Engineering, and Chair of the Joint UNC-NCSU Department of Biomedical Engineering.

gianpietro_dotti

Gianpietro Dotti, MD

Lineberger Comprehensive Cancer Center Immunotherapy Program

Current Projects

Dr. Dotti is a research professor of microbiology and immunology at UNC and Director of the Lineberger Comprehensive Cancer Center Immunotherapy Program.

zongchao_han

Zongchao Han, PhD

UNC’s School of Medicine Department of Ophthalmology

Dr. Han specializes in gene and drug delivery for retinal diseases.

Wei-Li Lin

Weili Lin, PhD

Biomedical Research Imaging Center

Dr. Lin’s is the Dixie Lee Boney Soo Distinguished Professor of Neurological Medicine and Director of the Biomedical Research Imaging Center (BRIC) at the University of North Carolina at Chapel Hill.

eric_bachelder

Eric Bachelder, PhD

Dr. Eric Bachelder focuses on the development of biomaterials for the treatment of diseases associated with the immune system.

Jillian Perry Image 2

Jillian Perry, PhD

Dr. Jillian Perry leverages her knowledge of polymer chemistry, biomaterials, and drug delivery to develop novel drug delivery carriers for the treatment of cancer and infectious diseases.

marina_sokolsky

Marina Sokolsky-Papkov, PhD

Dr. Marina Sokolsky-Papkov’s current research centers on design of nano-based, sustained release and remote actuated drug delivery systems for treatment and diagnosis of cancer.

john_fallon

John Fallon, PhD

Google Scholar

Dr. John Fallon’s research focuses on quantitative targeted proteomics (QTAP) using nano- and microLC-MS/MS.

Konstantin Lukianov, PhD

Google Scholar

Dr. Konstantin Lukianov focuses on development of genetically encoded fluorescent probes, and on mRNA delivery and protein engineering for vaccination.

Lindsay Androski, JD, MBA, CFA is Founder, President and CEO of Roivant Social Ventures, a social impact organization that makes early stage investments & incubates biotechs, with an emphasis on cell & gene therapies.

Edward Moreira Bahnson, PhD

Dr. Edward Bahnson’s research program focuses on the study of arterial disease, and developing new therapies to treat cardiovascular disease.

Ken Brouwer, PhD, RPh

Google Scholar

Dr. Ken Brouwer is Vice President of Technology, ADME-TOX at BioIVT, and has successfully lead and directed large international multidisciplinary project teams to support the product development of high priority development candidates.

David A. Zaharoff, PhD

Dr. David Zaharoff’s Lab focuses on the development of translatable immunotherapy delivery platforms. They use a multidisciplinary approach to engineer biomaterials-based and technology-driven localized immunotherapy strategies.

Geoffery Hird, PhD

Dr. Geoffrey Hird is the Chief Technology Officer at Glycomine and has more than 20 years of experience in all stages of pharmaceutical product development having held positions at Eisai, GSK, and Liquidia Technologies.

Kazunori Kataoka, PhD

Prof. Dr. Kazunori Kataoka is the Center Director of Innovation Center of NanoMedicine (iCONM), which is operated by Kawasaki Institute of Industrial Promotion. He is also an Emeritus Professor of the University of Tokyo.

Andrew_Satterlee

Andrew Satterlee, PhD

Google Scholar

Dr. Andrew Satterlee is associate director of the Brain Slice Technology Platform at UNC Eshelman School of Pharmacy.

Qi-Long Lu, PhD

Dr. Lu is Director of the McColl-Lockwood Laboratory for Muscular Dystrophy Research at Atrium Health. His main research interests are experimental therapies for limb girdle muscular dystrophies and is considered one of the world’s leading experts studying LGMD2i.

Lesley Marson, PhD

Dr. Lesley Marson was most recently Director of Sexual Health Research at Urogenix Inc. Prior to that she held the position of Professor in the Urology Division of the Department of Surgery, University of North Carolina, Chapel Hill.